Pfizer Inc. (PFE)
Pfizer raises annual profit forecast after better-than-expected COVID sales
U.S. drugmaker Pfizer on Tuesday raised its annual profit forecast after reporting better-than-expected sales of its COVID vaccine and antiviral treatment.
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Pfizer Inc. PFE is scheduled to release its financial results for the second quarter, before the opening bell on Tuesday.
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
Pfizer Inc. PFE will release its financial results for the second quarter, before the opening bell on Tuesday.
Prediction: This Will Be Pfizer's Next Big Move
Pfizer is in the midst of a strategic transition to new sources of revenue. It has enough capital to ease that transition by making acquisitions.
Pfizer And Merck's Earnings Previews: Uncorrelated To Big Tech, And Growth Styles
Both Merck and Pfizer are expected to report their Q2 '24 financial results on Tuesday morning, July 30 '24, before the opening bell. It's time for Pfizer to make hay after the pandemic spike, when the stock jumped from $30 in 2020 to $60 in late '21. Today, Merck is really all about Keytruda and what the pharma giant can squeeze from it, as it awaits further pipeline development.
High Yielding Pfizer Looks Bullish (Technical Analysis)
Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz. Technical analysis tools show bullish trends: trading above 30-week EMA, increasing momentum, and improving relative strength. Smart money buying, volume spikes, and breakout from consolidation suggest bullish outlook for Pfizer stock.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Will Pfizer Stock Post A Downbeat Q2?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis, lower than the consensus estimates.
Pfizer's Q2 Focus: Core Products And New Ventures
Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion. The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand. Investors are closely watching the performance of Pfizer's core products, particularly in oncology and vaccines, excluding COVID-19 products.
Seeking Clues to Pfizer (PFE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
Beware, Wegovy -- Pfizer Is Working on a Competitor
Pfizer's weight loss candidate is moving closer to pivotal studies. This product had encouraging results in phase 2 studies.
